Ongoing studies, such as this one [19], investigate the use of CSF‐1R inhibitor PLX3397 in the early stages of tumor development to increase the effectiveness of ICIs by boosting the number of CD8+ T cells, modifying the TME, and promoting “hot tumor” characteristics. Here, CSF1R is linked to neoplasm.